PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Clinical Investigation

• Publication date

  2013-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI68951PMID 23999433PMCID PMC3784537
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protein phosphatase 2A: a target for anticancer therapy.

  2013cited by this paper
• The Rac GTPase effector p21-activated kinase is essential for hematopoietic stem/progenitor cell migration and engraftment.

  2013cited by this paper
• Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.

  2012cited by this paper
• Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML.

  2012cited by this paper
• Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

  2012cited by this paper
• Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

  2011cited by this paper
• In Search of CML Stem Cells’ Deadly Weakness

  2011cited by this paper
• Antitumor effects of OSU‐2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma

  2011influential reference
• (R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: Effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells.

  2011cited by this paper
• AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3

  2010cited by this paper
• Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia

  2010influential reference
• Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.

  2010cited by this paper
• Clonal chromosomal abnormalities in CD34+/CD38− hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors

  2010cited by this paper
• Fingolimod is a potential novel therapy for multiple sclerosis

  2010cited by this paper
• In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib.

  2010influential reference
• Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML).

  2010cited by this paper
• BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells.

  2010cited by this paper
• Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.

  2010cited by this paper
• Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers.

  2010cited by this paper
• Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.

  2010cited by this paper
• Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo.

  2010cited by this paper
• Chronic myeloid leukemia: mechanisms of blastic transformation.

  2010cited by this paper
• FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

  2009influential reference
• Monitoring disease response to tyrosine kinase inhibitor therapy in CML.

  2009cited by this paper
• Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.

  2009cited by this paper
• PML targeting eradicates quiescent leukaemia-initiating cells

  2009cited by this paper
• Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients

  2009influential reference
• β-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia

  2009cited by this paper
• Protein Phosphatase 2 A and Rapamycin Regulate the Nuclear Localization and Activity of the Transcription Factor GLI 3

  2008cited by this paper
• Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells.

  2008cited by this paper
• Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation.

  2008cited by this paper
• PML targeting eradicates quiescent leukaemia-initiating cells

  2008cited by this paper
• Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo.

  2008cited by this paper
• Protein phosphatase 2A and rapamycin regulate the nuclear localization and activity of the transcription factor GLI3.

  2008cited by this paper
• Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

  2007cited by this paper
• Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells.

  2007cited by this paper
• Bcr‐Abl stabilizes β‐catenin in chronic myeloid leukemia through its tyrosine phosphorylation

  2007cited by this paper
• Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling.

  2007cited by this paper
• Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies

  2007cited by this paper
• FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

  2007influential reference
• Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo.

  2007influential reference
• Loss of β-Catenin Impairs the Renewal of Normal and CML Stem Cells In Vivo

  2007cited by this paper
• Wilms Tumor Suppressor WTX Negatively Regulates WNT/ß-Catenin Signaling

  2007cited by this paper
• Faculty Opinions recommendation of Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.

  2007cited by this paper
• Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720.

  2006cited by this paper
• Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.

  2006cited by this paper
• Identification of a tumour suppressor network opposing nuclear Akt function

  2006cited by this paper
• Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry.

  2006cited by this paper
• Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.

  2005cited by this paper
• Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.

  2005cited by this paper
• The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.

  2005influential reference
• Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli

  2005cited by this paper
• Iron-catalyzed cross-coupling reactions. A scalable synthesis of the immunosuppressive agent FTY720.

  2004cited by this paper
• Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.

  2004cited by this paper
• The sphingosine 1-phosphate receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD34+ progenitor cells.

  2004cited by this paper
• A role for Wnt signalling in self-renewal of haematopoietic stem cells

  2003cited by this paper
• DeltaNp63 induces beta-catenin nuclear accumulation and signaling.

  2002cited by this paper
• ΔNp63 induces β-catenin nuclear accumulation and signaling

  2002cited by this paper
• Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.

  2002cited by this paper
• BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.

  2002cited by this paper
• Iron-catalyzed cross-coupling reactions.

  2002cited by this paper
• BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2

  2002cited by this paper
• Involvement of Protein Phosphatase 2A in the Interleukin-3-Stimulated Jak2-Stat5 Signaling Pathway

  2001cited by this paper
• Investigation

  2000cited by this paper
• Human Immunodeficiency Virus Type 1 Spinoculation Enhances Infection through Virus Binding

  2000cited by this paper
• Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia.

  1999cited by this paper
• Regulation of β-Catenin Signaling by the B56 Subunit of Protein Phosphatase 2A

  1999cited by this paper
• Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A.

  1999influential reference
• A rapid RT-PCR based method for the detection of BCR-ABL translocation.

  1997cited by this paper
• Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice.

  1997cited by this paper
• Transformation of hematopoietic cells by BCR/ABL requires activation of a PI‐3k/Akt‐dependent pathway

  1997cited by this paper

• Understanding the regulatory landscape of protein phosphatase 2A (PP2A): Pharmacological modulators and potential therapeutics.

  2025cites this paper
• Acquired resistance to molecularly targeted therapies for cancer

  2025cites this paper
• AI-Driven Identification and Validation of RXFP1 as a CML Biomarker Using Gene Expression and Integrated GUI Tools

  2025influential citation
• A kinase-independent Bcr-Abl function mediating an Hsp70-Bim protein-protein interaction in chronic myeloid leukemia.

  2025cites this paper
• Targeting Musashi-2 to counteract senescence and resistance in chronic myeloid leukemia: enhancing the efficacy of imatinib therapy

  2025cites this paper
• H2AX phosphorylation driven by the SET-PP2A axis maintains glioma stem cell properties

  2025cites this paper
• Therapeutic Potential of Ceramide in Cancer Treatment.

  2024cites this paper
• Altering phosphorylation in cancer through PP2A modifiers

  2024cites this paper
• Novel Treatment Strategies for Chronic Myeloid Leukemia.

  2024cites this paper
• CDK8/19 inhibition attenuates G1 arrest induced by BCR-ABL antagonists and accelerates death of chronic myelogenous leukemia cells

  2024cites this paper
• BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph+ leukemias?

  2024cites this paper
• Anti-tumor activity of niclosamide-mediated oxidative stress against acute lymphoblastic leukemia.

  2024cites this paper
• Preclinical evaluation of cyclophosphamide and fludarabine combined with CD19 CAR-T in the treatment of B-cell hematologic malignancies in vivo

  2024influential citation
• Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2V617F myeloproliferative neoplasms

  2023cites this paper
• Always stressed but never exhausted: how stem cells in myeloid neoplasms avoid extinction in inflammatory conditions

  2023cites this paper
• Promising Molecular Targets in Pharmacological Therapy for Neuronal Damage in Brain Injury

  2023cites this paper
• In Silico and In Vivo Studies of a Tumor-Penetrating and Interfering Peptide with Antitumoral Effect on Xenograft Models of Breast Cancer

  2023cites this paper
• Regulation and role of the PP2A-B56 holoenzyme family in cancer.

  2023cites this paper
• Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders

  2023cites this paper
• Human pancreatic cancer patients with Epithelial-to-Mesenchymal Transition and an aggressive phenotype show a disturbed balance in Protein Phosphatase Type 2A expression and functionality

  2023cites this paper
• SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML

  2023influential citation
• Targeting SAMHD1: To overcome multiple anti-cancer drugs resistance in hematological malignancies

  2022cites this paper
• Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia

  2022influential citation
• BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia

  2022cites this paper
• Preclinical Validation of Tumor-Penetrating and Interfering Peptides against Chronic Lymphocytic Leukemia.

  2022cites this paper
• Thirty years of SET/TAF1β/I2PP2A: from the identification of the biological functions to its implications in cancer and Alzheimer’s disease

  2022cites this paper
• Targeting Sphingolipid Metabolism as a Therapeutic Strategy in Cancer Treatment

  2022cites this paper
• Genomic regulation of transcription and RNA processing by the multitasking Integrator complex

  2022cites this paper
• Pleiotropy of PP2A Phosphatases in Cancer with a Focus on Glioblastoma IDH Wildtype

  2022cites this paper
• PP2A and Its Inhibitors in Helper T-Cell Differentiation and Autoimmunity

  2022cites this paper
• Bi-Functional Peptides as a New Therapeutic Tool for Hepatocellular Carcinoma

  2021cites this paper
• Cancer stem cell phosphatases.

  2021cites this paper
• Treatment-Free Remission in Chronic Myeloid Leukemia and New Approaches by Targeting Leukemia Stem Cells

  2021cites this paper
• PPP2R4 dysfunction promotes KRAS-mutant lung adenocarcinoma development and mediates opposite responses to MEK and mTOR inhibition.

  2021cites this paper
• MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia by Enhancing Common β Chain Cytokine Receptor Endocytosis.

  2021cites this paper
• The Role of Ceramide Metabolism and Signaling in the Regulation of Mitophagy and Cancer Therapy

  2021cites this paper
• Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation

  2021cites this paper
• The Biology and Pathogenesis of Chronic Myeloid Leukaemia

  2021cites this paper
• Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms

  2021cites this paper
• Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?

  2021cites this paper
• Current Views on the Interplay between Tyrosine Kinases and Phosphatases in Chronic Myeloid Leukemia

  2021cites this paper
• CML Chapter.

  2021cites this paper
• The metabolic flexibility of quiescent CSC: implications for chemotherapy resistance

  2021cites this paper
• EGR1 dysregulation defines an inflammatory and leukemic program in cell trajectory of human-aged hematopoietic stem cells (HSC)

  2021cites this paper
• The Key Role of the Phosphatase PP2A in the Development of Acute Myeloid Leukemia

  2021cites this paper
• Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future

  2021cites this paper
• Druggable cancer phosphatases

  2021cites this paper
• Shedding Light on Targeting Chronic Myeloid Leukemia Stem Cells

  2021cites this paper
• Genetic Biomarkers in Chronic Myeloid Leukemia: What Have We Learned So Far?

  2021cites this paper
• Chronic myeloid leukemia stem cells: targeting therapeutic implications

  2021cites this paper
• miRNome profiling of LSC-enriched CD34+CD38−CD26+ fraction in Ph+ CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool

  2021cites this paper
• The interaction of SET and protein phosphatase 2A as target for cancer therapy.

  2021cites this paper
• Isolation of Primary Hepatocytes for Testing Tumor Penetrating Peptides.

  2021cites this paper
• Antioxidants

  2020cites this paper
• PP2A and tumor radiotherapy

  2020cites this paper
• DYRK2 controls a key regulatory network in chronic myeloid leukemia stem cells

  2020cites this paper
• Bifunctional Therapeutic Peptides for Targeting Malignant B Cells and Hepatocytes: Proof of Concept in Chronic Lymphocytic Leukemia

  2020cites this paper
• The Greatwall kinase safeguards the genome integrity by affecting the kinome activity in mitosis

  2020cites this paper
• Sphingosine Analogs and Protein Phosphatase 2A as a Molecular Targeted Cancer Therapy: A Mini Systematic Review

  2020cites this paper
• Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions.

  2020influential citation
• An okadaic acid fragment analogue prevents nicotine-induced resistance to cisplatin by recovering PP2A activity in non-small cell lung cancer cells.

  2020cites this paper
• Serine/Threonine Phosphatases in Osteoclastogenesis and Bone Resorption.

  2020cites this paper
• Declaration of Bcr-Abl1 independence

  2020cites this paper
• The Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias

  2020cites this paper
• Monotherapy efficacy of blood–brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma

  2020influential citation
• Monotherapy efficacy of BBB-permeable small molecule activators of PP2A in glioblastoma

  2019cites this paper
• A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity.

  2019cites this paper
• The role of exosomes and MYC in therapy resistance of acute myeloid leukemia: Challenges and opportunities.

  2019cites this paper
• Penfluridol triggers cytoprotective autophagy and cellular apoptosis through ROS induction and activation of the PP2A-modulated MAPK pathway in acute myeloid leukemia with different FLT3 statuses

  2019cites this paper
• Efficacy of an anti-cancer strategy targeting SET in canine osteosarcoma

  2019cites this paper
• BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia

  2019influential citation
• Leukemia Stem Cells in the Pathogenesis, Progression, and Treatment of Acute Myeloid Leukemia.

  2019cites this paper
• Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration

  2019cites this paper
• Human BCR/ABL1 induces chronic myeloid leukemia-like disease in zebrafish

  2019cites this paper
• Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells

  2019cites this paper
• Cyclin-dependent kinase 1-mediated phosphorylation of SET at serine 7 is essential for its oncogenic activity

  2019cites this paper
• Chronic myeloid leukemia stem cells

  2019cites this paper
• Response to Comment on “PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia”

  2019cites this paper
• RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth

  2019cites this paper
• Targeting PP2A in cancer: Combination therapies.

  2019cites this paper
• Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells

  2019cites this paper
• Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update

  2019cites this paper
• Chronic myelogenous leukemia Chronic myeloid leukemia stem cells

  2019cites this paper
• Comment on “PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia”

  2019cites this paper
• Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer.

  2018cites this paper
• Transient PP2A inhibition alleviates normal tissue stem cell susceptibility to cell death during radiotherapy

  2018cites this paper
• PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia

  2018cites this paper
• The JAK2 blocker TG101209 is a potent inhibitor of clonogenic progenitor cell growth in patients with chronic myeloid leukaemia

  2018cites this paper
• Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain

  2018cites this paper
• Xiao-AiPing inhibits proliferation and induces apoptosis of chronic myeloid leukemia cells through downregulating β-catenin signaling pathway

  2018cites this paper
• Receptor-interacting Ser/Thr kinase 1 (RIPK1) and myosin IIA–dependent ceramidosomes form membrane pores that mediate blebbing and necroptosis

  2018cites this paper
• Tonic ATP-mediated growth suppression in peripheral nerve glia requires arrestin-PP2 and is evaded in NF1

  2018cites this paper
• Benzene-induced mouse hematotoxicity is regulated by a protein phosphatase 2A complex that stimulates transcription of cytochrome P4502E1

  2018cites this paper
• Targeting chronic myeloid leukemia stem cells: can transcriptional program be a druggable target for cancers?

  2018cites this paper
• Mechanisms of Ceramide-Dependent Cancer Cell Death.

  2018cites this paper
• Targeted therapies don't work for a reason; the neglected tumor suppressor phosphatase PP2A strikes back

  2018cites this paper
• Identification of PP2A/Set Binding Sites and Design of Interacting Peptides with Potential Clinical Applications

  2018cites this paper
• Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia

  2018cites this paper
• Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment.

  2018cites this paper
• Expression analysis of Akirin-2, NFκB-p65 and β-catenin proteins in imatinib resistance of chronic myeloid leukemia

  2018cites this paper